Fructus Ligustrum lucidi inhibits inflammatory mediator release through inhibition of nuclear factor-kappaB in mouse peritoneal macrophages.
Fructus Ligustrum lucidi (FLL) is a widely used herbal medicine for the treatment of a variety of pathologies. We have investigated the anti-inflammatory mechanism of FLL in mouse peritoneal macrophages. FLL exerted an anti-inflammatory action through inhibition of lipopolysaccharide (LPS)-induced tumour necrosis factor (TNF)-alpha production in mouse peritoneal macrophages. The maximal inhibition rate of TNF-alpha production by FLL (0.5 mg mL(-1)) was 60.88 +/- 0.30%. In the inflammatory process, nitric oxide (NO) and prostaglandin E(2) (PGE(2)) increased in peritoneal macrophages. FLL decreased the protein level of NO and PGE(2) in LPS-stimulated mouse peritoneal macrophages. In addition, FLL inhibited nuclear factor-kappaB activation and IkappaB-alpha degradation by the decrease in IkappaB-alpha phosphorylation. Our study suggested that FLL reduced inflammation via an important molecular mechanism, which might explain its beneficial effect in the regulation of inflammatory reactions.
An
Hyo-Jin
HJ
College of Oriental Medicine, Institute of Oriental Medicine, Oriental Medical Science Center, Kyung Hee University, 1-Hoegi-Dong, Dongdaemun-Gu, Seoul 130-701, Republic of Korea.
Jeong
Hyun-Ja
HJ
Um
Jae-Young
JY
Park
Yun-Jum
YJ
Park
Rae-Kil
RK
Kim
Eun-Cheol
EC
Na
Ho-Jeong
HJ
Shin
Tae-Yong
TY
Kim
Hyung-Min
HM
Hong
Seung-Heon
SH
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D015153:Blotting, Western; D015232:Dinoprostone / Q000378:metabolism; D005638:Fruit; D020672:I-kappa B Proteins / Q000187:drug effects / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy*; D031659:Ligustrum / Q000737:chemistry*; D008070:Lipopolysaccharides; D017737:Macrophages, Peritoneal / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D010766:Phosphorylation; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; D016328:NF-kappa B; C000606205:Nfkbia protein, mouse; D014409:Tumor Necrosis Factor-alpha; D000072000:NF-KappaB Inhibitor alpha; D009569:Nitric Oxide; D015232:Dinoprostone